Peptimmune Overview
- Year Founded
-
2002
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Liquidation
Peptimmune General Information
Description
Developer of peptide and peptide-copolymer therapeutics for the treatment of CNS and autoimmune disorders. The company provides PI-2301 peptide copolymer for the treatment of multiple sclerosis; and DEEP vaccines for viral, bacterial, and parasitic infectious diseases.
Contact Information
Website
www.peptimmune.comCorporate Office
- 64 Sidney Street
- Suite 380
- Cambridge, MA 02139
- United States
Corporate Office
- 64 Sidney Street
- Suite 380
- Cambridge, MA 02139
- United States
Peptimmune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Bankruptcy: Liquidation | 23-Mar-2011 | Completed | Bankruptcy: Liquidation | |||
| 4. Later Stage VC (Series D) | 17-Jan-2008 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 15-Jul-2005 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 04-Mar-2003 | $41.2M | $46.7M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 19-Jan-2002 | $5.5M | $5.5M | Completed | Product Development |
Peptimmune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 25,242,857 | $0.010000 | 6% | $1.05 | $1.05 | 1x | $172.72 | 3.84% |
| Series A | 5,500,000 | $0.010000 | 6% | $1 | $1 | 1x | $126.82 | 1.08% |
Peptimmune Patents
Peptimmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2011063043-A1 | Methods for improving the design, bioavailability, and efficacy of directed sequence polymer compositions via serum protein-based detection of directed sequence polymer compositions | Inactive | 17-Nov-2009 | ||
| WO-2011063045-A1 | Methods for improving the design, bioavailability, and efficacy of random sequence polymer compositions via serum protein-based detection of random sequence polymer compositions | Inactive | 17-Nov-2009 | ||
| WO-2009128948-A1 | Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders | Inactive | 17-Apr-2008 | ||
| WO-2009075854-A2 | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods | Inactive | 10-Dec-2007 | ||
| WO-2009075854-A3 | Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods | Inactive | 10-Dec-2007 | A61K38/16 |
Peptimmune Signals
Peptimmune FAQs
-
When was Peptimmune founded?
Peptimmune was founded in 2002.
-
Where is Peptimmune headquartered?
Peptimmune is headquartered in Cambridge, MA.
-
What is the size of Peptimmune?
Peptimmune has 5 total employees.
-
What industry is Peptimmune in?
Peptimmune’s primary industry is Pharmaceuticals.
-
Is Peptimmune a private or public company?
Peptimmune is a Private company.
-
What is Peptimmune’s current revenue?
The current revenue for Peptimmune is .
-
How much funding has Peptimmune raised over time?
Peptimmune has raised $90.5M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process